This investigation reports on the biochemical and clinical outcomes of a newly created pan-Canadian Prostate Cancer Risk Stratification (ProCaRS) database developed by the Genitourinary Radiation Oncologists of Canada (GUROC).
GUROC ProCaRS template-compliant data on 7974 patients who underwent radiotherapy were received from 7 unique databases. Descriptive analysis, Cox proportional hazards, and Kaplan-Meier analyses were performed using American Society for Radiation Oncology (ASTRO) biochemical failure-free survival (BFFS), prostate cancer-specific survival, and overall survival. Multivariable modeling for the primary ASTRO BFFS end point showed that age, prostate-specific antigen, T stage, and Gleason score and components such as hormonal therapy, and radiation treatment (brachytherapy with better outcome than external-beam) were predictive of outcome. Kaplan-Meier analysis of the existing GUROC and new NCCN classification system both showed good separation of all clinical outcome curves. The construction of a pan-Canadian database has informed important prostate cancer radiotherapy outcomes and risk stratification.
Written by:
Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, Cury F, Catton C, Mok G, Martin AG, Vigneault E, Morris J, Warner A, Maldonado SG, Pickles T. Are you the author?
Department of Radiation Oncology, London Health Sciences Centre, London, Ontario; Department of Radiation Oncology, Juravinski Cancer Centre, Hamilton, Ontario; Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Ontario; Department of Radiation Oncology, Kingston Regional Cancer Centre, Kingston, Ontario; Department of Radiation Oncology, Montreal General Hospital, Montreal, Quebec; Department of Radiation Oncology, Kelowna General Hospital, Kelowna, British Columbia; Department of Radiation Oncology, L'Hotel Dieu de Quebec, Quebec City, Quebec; Department of Radiation Oncology, British Columbia Cancer Agency - Vancouver Centre, Vancouver, British Columbia, Canada.
Reference: J Natl Compr Canc Netw. 2014 Jan 1;12(1):60-9.
PubMed Abstract
PMID: 24453293
UroToday.com Prostate Cancer Section
